メインナビゲーションにスキップ
検索にスキップ
メインコンテンツにスキップ
Keio University ホーム
ヘルプ＆FAQ
English
日本語
ホーム
プロファイル
研究部門
研究成果
専門知識、名前、または所属機関で検索
Scopus著者プロファイル
畔上 達彦
内科学(腎臓・内分泌・代謝)
ウェブサイト
https://k-ris.keio.ac.jp/html/100013766_ja.html
h-index
944
被引用数
18
h 指数
Pureの文献数とScopusの被引用数に基づいて算出されます
2010
2025
年別の研究成果
概要
フィンガープリント
ネットワーク
研究成果
(66)
類似のプロファイル
(6)
フィンガープリント
Tatsuhiko Azegamiが活動している研究トピックを掘り下げます。このトピックラベルは、この研究者の研究成果に基づきます。これらがまとまってユニークなフィンガープリントを構成します。
並べ替え順
重み付け
アルファベット順
Medicine and Dentistry
Peritoneal Dialysis
67%
Chronic Kidney Disease
65%
Proteinuria
58%
Podocyte
55%
DNA Methylation
50%
Infection
45%
Blood Pressure
44%
DNA Damage
39%
Retrospective Cohort Study
36%
Immunoglobulin A Nephropathy
35%
Kidney Function
33%
Cohort Analysis
33%
Glomerular Filtration Rate
30%
Body Mass Index
29%
Angiotensin
25%
Biopsy
24%
Glomerulopathy
23%
Angiotensin II
23%
Nephrin
22%
Glomerulus Filtration
22%
Odds Ratio
21%
Cardiovascular Disease
20%
End Stage Renal Disease
20%
Hemodialysis
18%
Double Stranded DNA
18%
Low Birth Weight
18%
Renal Replacement Therapy
17%
Birth Weight
17%
Angiotensin Receptor
16%
Dentistry
16%
Injury
16%
Plasminogen Activator Inhibitor-1
16%
Adolescent
16%
End Organ Damage
16%
DNA Repair
16%
Endothelium Injury
16%
Cognition
16%
Cytotoxic T-Cell
16%
Dialysis Catheter
16%
Kidney Injury
16%
Fibronectin
16%
Sodium Zirconium Cyclosilicate
16%
Hemodynamic
16%
Visceral Fat
16%
Receptor
16%
Membrane Protein
16%
Membranoproliferative Glomerulonephritis
16%
Meta-Analysis
16%
Renin
16%
Systematic Review
16%
Pharmacology, Toxicology and Pharmaceutical Science
Chronic Kidney Failure
100%
Vaccination Policy
64%
Cohort Study
53%
Mouse
37%
Atherosclerosis
33%
Nanogel
33%
Angiotensin II
33%
Dapagliflozin
33%
Angiotensin Receptor Antagonist
31%
Disease
29%
Cardiovascular Disease
28%
Infection
25%
Antiobesity Agent
25%
End Stage Renal Disease
24%
Glomerulosclerosis
23%
Candesartan
23%
Low Birth Weight
22%
Sodium Glucose Cotransporter 2 Inhibitor
20%
Mouse Model
20%
Therapeutic Effect
19%
Nasal Vaccine
19%
Angiotensin
17%
Plasminogen Activator Inhibitor 1
16%
Angiotensin Receptor
16%
Receptor
16%
Oral Vaccine
16%
Thymus and Activation Regulated Chemokine
16%
Pneumococcal Infection
16%
Kidney Fibrosis
16%
Sodium Zirconium Cyclosilicate
16%
Hemodialysis
16%
Graft Failure
16%
Good Manufacturing Practice
16%
Membrane Protein
16%
Connective Tissue Growth Factor
16%
Vaccine Development
16%
Drug Delivery System
16%
Apolipoprotein E
16%
Gelatinase A
16%
Pruritus
16%
SARS Coronavirus
16%
Therapeutic Vaccine
16%
Cotransporter
16%
Table Salt
16%
Proteinuria
16%
Nephrotic Syndrome
16%
Hypertension
16%
Malignant Neoplasm
16%
Icodextrin
16%
Tolvaptan
16%
Keyphrases
Estimated Glomerular Filtration Rate
66%
Proteinuria
52%
Chronic Kidney Disease
51%
Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i)
37%
Hypertension
35%
Podocyte
33%
KAT5
33%
DNA Methylation (DNAm)
33%
Vaccination
33%
Dapagliflozin
33%
Kidney Outcomes
33%
Chronic Kidney Disease Patients
27%
Body Mass Index
26%
EGFR Decline
25%
Renin-angiotensin System
22%
Clinical Significance
21%
DNA Damage
19%
Dose Effect
18%
Decline in Kidney Function
18%
Older Adults
18%
Female Adolescents
16%
Adolescent Males
16%
Angiotensin Type I Receptor
16%
Obesity
16%
Atherosclerosis Regression
16%
Preemptive Kidney Transplantation
16%
Fibronectin Glomerulopathy
16%
Chronic Kidney Disease-associated Pruritus
16%
Intranasal Vaccination
16%
Oral Vaccine
16%
Rice-based Vaccine
16%
DNA Repair Factors
16%
Glomerular Filtration
16%
Obesity Prevention
16%
Regret
16%
Japanese Workers
16%
Birth Weight
16%
Low Birth Weight
16%
Laboratory Parameters
16%
Angiotensin II Blockers
16%
Sodium Zirconium Cyclosilicate
16%
Salt Intake
16%
Exit Site Care
16%
Sars-cov-2 Infection
16%
Cellular Crosstalk
16%
Modality Education
16%
Haematologic Values
16%
Systematic Meta-analysis
16%
Biochemical Values
16%
Oral Cholera Vaccine
16%
